PRA Health Sciences
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
 PRA Health Sciences logo 2014 | |
| Company type | Public |
|---|---|
| Industry | Pharmaceuticals & Biotechnology |
| Founded | 1976 Charlottesville, Virginia, U.S. |
| Headquarters | , U.S. |
Area served | Worldwide |
Key people | Colin Shannon (President and CEO) |
| Revenue | |
Number of employees | 17,000+[1] |
| Website | prahs |
PRA Health Sciences is a contract research organization (CRO) with headquarters in Raleigh, North Carolina that was founded in 1982.[2] In 2013 the company was acquired by Kohlberg Kravis Roberts, which brought the company public in November 2014 and maintained shares until September 2019.[3]
In August 2017 the company acquired Conshohocken-based real-world healthcare data, analytics, and technology solutions company Symphony Health for US$530 million.[4]
In November 2019 PRA announced it was partnering with Johnson & Johnson pharmaceutical arm Janssen Pharmaceutica in a first-of-its-kind decentralized clinical trial evaluating the drug Invokana (canagliflozin) in adults with heart failure, with preserved or reduced ejection fraction, with or without type 2 diabetes. This landmark study will collect real-world evidence via a mobile clinical trial platform. [5]
PRA's 2018 revenue was US$2.87 billion.[6]
References
- ^ a b c "PRA 10-K For the fiscal year ended December 31, 2017". PRA Health Sciences via SEC Edgar. 2018-02-02. See SEC Edgar index page for PRA for updates
- ^ "PRA Health Sciences becomes latest big CRO to launch IPO". CenterWatch News Online. 13 November 2014.
- ^ "PRA Health Sciences Announces Secondary Offering and Concurrent Share Repurchase". Globenewswire. September 3, 2019.
- ^ Liu, Angus (August 8, 2017). "PRA Health Sciences makes $530M Symphony buy, reports 16% revenue growth in Q2". FierceBiotech.
- ^ "AHA: Janssen drops clinical sites for smartphones, wearables in 100% virtual Invokana study". FierceBiotech. November 16, 2019.
- ^ https://investor.prahs.com/static-files/06f80501-79f0-4108-a719-1c54796903ba